Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 11/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.58 |
| ▸ | IL1RN | P18510 | 6/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018948 | 0.94 | ERAP2 (0.66) | ERAP2KISS1RNPBWR1IL1RNERAP1 | |
| SCHEMBL18862075 | 0.90 | NPBWR1 (0.60) | ERAP2NPBWR1 | |
| SCHEMBL30065757 | 0.89 | ERAP2 (0.65) | ERAP2KISS1RNPBWR1IL1RNERAP1 | |
| SCHEMBL31031505 | 0.88 | ERAP2 (0.59) | ERAP2KISS1RNPBWR1IL1RNERAP1 | |
| SCHEMBL30839328 | 0.88 | ERAP2 (0.73) | ERAP2IL1RNERAP1 | |
| SCHEMBL29354013 | 0.88 | ERAP2 (0.76) | ERAP2IL1RNERAP1 | |
| SCHEMBL20764526 | 0.87 | ERAP2 (0.70) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL9842926 | 0.85 | ERAP2 (0.68) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL31247322 | 0.85 | ERAP2 (0.66) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL29987530 | 0.85 | ECE1 (0.64) | ERAP2IL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091318-A1 | COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091318-A1 | COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS | GLP1R, NPY4R, NPY2R | ERAP2 1407/4885KISS1R 166/4885NPBWR1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.